Xpovio (Selinexor) 20mg Tablets — XPO1 Inhibitor for Multiple Myeloma | USA | GLT

Generic Information: Xpovio (Selinexor) — United States

Xpovio (generic name selinexor) is the US FDA-approved, first-in-class oral Selective Inhibitor of Nuclear Export (SINE) developed by Karyopharm Therapeutics of Newton, Massachusetts. It received initial FDA approval for relapsed/refractory multiple myeloma, and a subsequent approval in combination with bortezomib and dexamethasone (XVd). Outside the United States the same molecule is marketed as Nexpovio (Europe) and Xpovio (China, via Antengene). This listing is the US originator version, the reference product against which all selinexor generics are measured.

Selinexor is the only approved drug that targets XPO1-mediated nuclear export, giving it a mechanism entirely distinct from the proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies that dominate myeloma treatment. This makes it a meaningful option for patients whose disease has become refractory to those standard classes.

What Is Xpovio (Selinexor) Tablets?

Xpovio is an oral tablet of selinexor. The US product is supplied in multiple tablet strengths — 10 mg, 20 mg, 40 mg, 50 mg, 60 mg, and 80 mg — to support the different dosing regimens. The 20 mg strength listed here is a core dose used to build up the weekly schedules. As an oral medicine taken once or twice weekly, it offers patients a far more convenient route than injectable myeloma regimens.

How Does Xpovio (XPO1 Inhibitor) Work?

Xpovio binds selectively to XPO1, the protein responsible for exporting more than 200 cargo proteins — including key tumor suppressors — out of the cell nucleus. In cancer cells, this export pathway is hyperactive, clearing tumor-suppressor proteins like p53 and p21 before they can act. By locking XPO1, selinexor traps these suppressors in the nucleus, restoring their anti-cancer activity and driving selective apoptosis of malignant plasma cells while largely sparing normal cells.

Indications for Xpovio (Selinexor)

• In combination with bortezomib and dexamethasone (XVd) for adult patients with multiple myeloma who have received at least one prior therapy.
• In combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

Dosage of Xpovio 20 mg

In the XVd regimen, the recommended dose is 100 mg once weekly; in the Xd regimen it is 80 mg on Days 1 and 3 of each week. Because doses are assembled from the available tablet strengths, the 20 mg tablet is a frequently used component. Dosing is modified for low blood counts and adverse reactions, and for patients with severe hepatic impairment.

Side Effects of Xpovio (Selinexor)

Clinically important adverse reactions include thrombocytopenia, neutropenia, nausea, vomiting, diarrhea, anorexia, and weight loss. Hyponatremia, serious infections, neurological toxicity (dizziness, confusion), and cataracts have also been reported. Frequent blood-count monitoring is required. Patients should be counseled about the risk of fetal harm and advised to use effective contraception.

Storage of Xpovio Tablets

Keep Xpovio at room temperature in its original blister packaging, protected from moisture and light, out of reach of children. Do not take the tablet out of its blister until just before dosing.

Why Choose the GLT?

The US Xpovio is a high-priced specialty medicine — its list price in the United States is among the highest in oncology, in the tens of thousands of dollars per treatment cycle. GIVE LIFE TIME LIMITED (GLT) helps international institutional and individual buyers obtain genuine selinexor through multi-country sourcing, including the US originator, the China version, and trusted generics from Laos and Bangladesh, so that buyers can select the option that best balances authenticity, regulatory status, and budget. We verify every source and provide clear guidance on the differences between the originator and generic versions.

How to Order Xpovio (Selinexor)

To order Xpovio (selinexor) or to compare the US originator against more affordable China or generic selinexor options, contact GIVE LIFE TIME LIMITED (GLT). We serve licensed business buyers and individual patients. Reach us on WhatsApp at +86 15234153837 or by email at [email protected].

FAQ: Xpovio (Selinexor) US Version

Q: Who makes the US Xpovio?
A: Xpovio is developed and marketed in the United States by Karyopharm Therapeutics, which discovered selinexor.

Q: Is there a generic version of selinexor?
A: Generic selinexor versions are available from manufacturers in Laos and Bangladesh; GLT can source both the originator and these generics.

Q: What is selinexor used for?
A: Relapsed/refractory multiple myeloma, either with dexamethasone or in the XVd combination with bortezomib and dexamethasone.

Q: Why is the US Xpovio so expensive?
A: The US list price of Xpovio is set at a premium specialty-oncology level. Buyers seeking a lower-cost route often consider the China version or a generic.

Q: How do I order selinexor?
A: Contact GLT on WhatsApp +86 15234153837 or email [email protected] to discuss availability and sourcing options.